In vivo CRISPR screening identifies POU3F3 as a novel regulator of ferroptosis resistance in hepatocellular carcinoma via retinoic acid signaling

In vivo CRISPR screening identifies POU3F3 as a novel regulator of ferroptosis resistance in hepatocellular carcinoma via retinoic acid signaling

Abstract Background Sorafenib, a ferroptosis agonist, is a first-line treatment for advanced hepatocellular carcinoma (HCC). However, its clinical efficacy is limited due to drug resistance, resulting in modest improvements in patient survival. Hence, the present study has been designed to identify...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu Tian, Xin Bao, Shan Lei, Youcai Huang, Xiaoling Wang, Yanyang Tu, Qinglian He, Feixiang Zhang, Haicheng Xu, Milad Ashrafizadeh, Gautam Sethi, Furong Wang, Zhirui Zeng
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Cell Communication and Signaling
Subjects:
Hepatocellular carcinoma
CRISPR library screening
Sorafenib
Retinoic acid metabolism
POU3F3
Online Access:https://doi.org/10.1186/s12964-025-02285-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12964-025-02285-x

Similar Items